Cell2Cure (C2C) has entered into a collaboration agreement with Cbio A/S to establish C2C´s own GMP facility for production of adipose tissue-derived mesenchymal stromal cell products (ASCs) in Cbio´s newly established and approved cell production facility, Transformervej 8, 2860 Søborg, Denmark.

Cell2cure has a license from Rigshospitalet, Copenhagen, to a proprietary ASC production technology platform and have established cell products, which already has proven safety and promising clinical results in clinical trials involving > 300 patients.

C2C will in the new facilities further develop its ASC product portfolio and continue clinical development programs for diseases with inflammatory, immunological and tissue/function re-generation components involved.